|
Mar 13
|
InspireMD Full Year 2024 Earnings: US$0.76 loss per share (vs US$0.82 loss in FY 2023)
|
|
Mar 13
|
InspireMD Inc (NSPR) Q4 2024 Earnings Call Highlights: Revenue Growth Amid Rising Expenses and ...
|
|
Mar 12
|
InspireMD Reports Fourth Quarter and Full Year 2024 Financial Results
|
|
Feb 24
|
Investors in InspireMD (NASDAQ:NSPR) have unfortunately lost 78% over the last five years
|
|
Jan 21
|
InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|
|
Oct 8
|
InspireMD Advances with FDA Study Approval and Global Goals
|
|
Oct 7
|
InspireMD Announces Approval of Investigational Device Exemption (IDE) Application for CGUARDIANS II Pivotal Study of the CGuard Prime 80cm Carotid Stent System
|
|
Jul 30
|
InspireMD to Report Second Quarter 2024 Financial Results and Provide Corporate Business Update on Tuesday, August 6th
|
|
May 14
|
InspireMD Reports First Quarter 2024 Financial Results and Provides Business Update
|
|
May 14
|
InspireMD Insider Ups Holding By 13% During Year
|
|
May 7
|
InspireMD to Report First Quarter 2024 Financial Results and Provide Corporate Business Update on Tuesday, May 14th
|
|
Apr 3
|
InspireMD to Present at the 23rd Annual Needham Virtual Healthcare Conference
|
|
Mar 31
|
InspireMD's (NASDAQ:NSPR) investors will be pleased with their solid 110% return over the last year
|
|
Mar 26
|
InspireMD Announces Abstract of One-Year Follow-Up Results from the C-GUARDIANS U.S. Investigational Device Exemption (IDE) Clinical Trial Accepted for Presentation at LINC 2024
|
|
Mar 7
|
InspireMD, Inc. (NASDAQ:NSPR) Q4 2023 Earnings Call Transcript
|
|
Mar 6
|
InspireMD Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update
|
|
Feb 12
|
InspireMD Appoints Principal Investigators for C-GUARDIANS II Clinical Trial of the SwitchGuard™ Neuroprotection System
|
|
Dec 20
|
InspireMD Announces Issuance of Key U.S. Patent Covering Its SwitchGuard™ Neuroprotection System
|
|
Dec 6
|
InspireMD's Gary Roubin Acquires 13% More Stock
|
|
Nov 27
|
InspireMD Announces Strategic Agreement with Jacobs Institute to Execute Early Feasibility Study of CGuard EPS for the Treatment of Acute Stroke Patients with Tandem Lesions
|